Previously, the first‐generation ALK‐tyrosine kinase inhibitor (TKI) crizotinib was the standard treatment for newly diagnosed cases of ALK rearrangement NSCLC, because crizotinib showed a response rate of more than 60% and a median progression‐free survival (PFS) of approximately one year in clinical trials.3 However, there was a problem because resistance developed within a couple of years after the treatment started in most of the patients. Here, ALK is linked to non-small cell lung carcinoma.